Immune Design: Corporate Overview (Immune Design) - Mar 5, 2016 - Anticipated early data from P1 trial (NCT02387125) for ovarian cancer at ASCO (June 3-7, 2016); Anticipated analysis from initial 40 patients of P2 trial (NCT02609984) for soft tissue sarcoma in 2016; Anticipated FDA meeting regarding P2 data of soft tissue sarcoma in 2016; Anticipated complete data from P2 trial (NCT02609984) for soft tissue sarcoma at ASCO (June 2-6, 2017); Anticipated BLA filing for soft tissue sarcoma in 2018
Anticipated FDA event • Anticipated NDA • Anticipated P1 data • Anticipated P2 data • Oncology • Ovarian Cancer • Sarcoma
|